Compare MBAI & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBAI | BNGO |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 11.6M |
| IPO Year | N/A | 2018 |
| Metric | MBAI | BNGO |
|---|---|---|
| Price | $1.62 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 161.0K | ★ 221.2K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000,735.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.26 |
| 52 Week Low | $1.31 | $1.06 |
| 52 Week High | $3.92 | $5.50 |
| Indicator | MBAI | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 35.69 |
| Support Level | $1.31 | $1.06 |
| Resistance Level | $1.87 | $1.64 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 33.49 | 43.75 |
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.